Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis.

ABSTRACT: Lymphatic filariasis infects over 120 million people worldwide and can lead to significant disfigurement and disease. Resistance is emerging with current treatments, and these therapies have dose limiting adverse events; consequently new targets are needed. One approach to achieve this goal is inhibition of parasitic protein kinases involved in circumventing host defense mechanisms. This report describes structure-activity relationships leading to the identification of a potent, orally bioavailable stress activated protein kinase inhibitor that may be used to investigate this hypothesis.

SUBMITTER: Tummalapalli SR 

PROVIDER: S-EPMC5846038 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature